All Stories

UPDATED: Hedge fund aims to oust Depomed board for ‘troubling record’

Eric Palmer If Depomed thought it was free to chart its own course after foiling a takeover by Horizon Pharma last year, it can think again. A hedge fund practiced in the art of board ...

Buyers eye Relypsa and its hyperkalemia drug

Eric Palmer Redwood City, CA-based Relypsa has hired an investment bank to check out M&A offers, Reuters reported. Relypsa isn't commenting but the news service says several ...

Kenneth Bloom named president at Human Longevity

Alok Saboo In this week's Chutes and Ladders, Kenneth Bloom has been named president of Human Longevity and Kevin Herde has been selected to be CFO of Sorrento. Plus more hirings ...

New name, but same old problems for Posimir as FDA hits Durect again

Ben Adams Durect may have changed the name of its post-pain gall bladder surgery drug from "Posidur" to "Posimir" this year, but this has not stopped its run of ...

Pfizer investors stand with CEO Read even though he is 0 for 2 on megamergers

Eric Palmer Pfizer CEO Ian Read walked away from its $ 160 billion merger with Allergan this week after U.S. Treasury Department rule changes sucked the value out of its tax inversion ...

Big Pharma trio backs cancer startup; AB jumps on ALS data; Shire founder oversees AIM listing

Nick Paul Taylor In this week's EuroBiotech Report, Metabomed celebrated adding Pfizer to a list of investors that already featured the VC units of Merck KGaA and Boehringer Ingelheim. ...

Experts worry insulin getting too expensive for many in U.S. and worldwide

Eric Palmer Healthcare professionals are concerned that hormone insulin meds, often the key diabetes treatment, are getting too costly for many patients, even in the U.S. In developing ...

Aeglea raises $50M in IPO after slashing share price

John Carroll Austin, TC-based Aeglea BioTherapeutics raised $ 50 million in its IPO after pricing 5 million shares at $ 10 each, far below the range that it had set out for itself. FierceBiotech ...

Allergan takes Linzess on a run with differentiation push

Carly Helfand Every drugmaker wants to find differentiators for their products. And for Ironwood, it was obvious. "Is this a constipation drug that improves abdominal symptoms, ...

A-listers provide a $50M B round to AstraZeneca’s antibiotics spinout Entasis

John Carroll Last summer, AstraZeneca formally spun out its pared-down early-stage antibiotics unit in Waltham, MA, as Entasis Therapeutics, bequeathing a $ 40 million A round for ...

ACC latest: Lilly, Merck, Pfizer, Novartis and more unveil key data

Tracy Staton You missed the American College of Cardiology meeting. That's OK. The most newsworthy research coming out of the meeting is gathered right here, with almost every Big ...

Harvard, Tufts med students stage protest at ‘biased’ $2.9B drug development figure

Ben Adams Around two dozen students from Harvard Medical School and Tufts University as well as members of health activist groups protested in front of the Tufts Center for the Study ...
Page 1 of 83912345...102030...Last »
© 2016 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS